Abstract: ¹³¹I labeled mouse-human chimeric tumor necrosis therapy monoclonal antibody(¹³¹I-chTNT) is a kind of new drug targeting at degenerated or necrotic nuclei in the tumor necrosis zone, and may be applicable to the majority of human solid tumors, such as lung cancer, liver cancer, colon carcinoma and glioma, while conventional tumor cell monoclonal antibody can target only tumor cell surface antigen. Enhanced effects can be achieved by ¹³¹I-chTNT in combination with other therapies, such as radiotherapy, chemotherapy or radiofrequency ablation, which may increase tumor necrosis region and expose more combinative targets.